Compare SOAR & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOAR | GDTC |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | Singapore |
| Employees | 13 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.4M |
| IPO Year | N/A | 2021 |
| Metric | SOAR | GDTC |
|---|---|---|
| Price | $0.14 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 43.0K |
| Earning Date | 05-15-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.68 |
| 52 Week High | $4.36 | $3.68 |
| Indicator | SOAR | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 35.19 |
| Support Level | $0.12 | $0.71 |
| Resistance Level | $0.19 | $1.12 |
| Average True Range (ATR) | 0.01 | 0.11 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 16.11 | 21.06 |
Volato Group Inc is an aviation technology company that connects travelers to private, on-demand flight access and develops proprietary software platforms for enterprise and operational applications. The company operates in a single operating and reportable segment, private aviation services. It operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.